News
-
-
-
COMMUNIQUÉ DE PRESSE
Biocon's Pertuzumab Becomes First Biosimilar to Secure EMA CHMP Approval Recommendation Under New Tailored Clinical Approach
Biocon's Pertuzumab, the first biosimilar to secure EMA CHMP approval, marks a milestone in biosimilar science, granting access to HER2-positive breast cancer treatment in Europe -
-
-